Literature DB >> 2611194

Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

J Villumsen1, A Alm, M Söderström.   

Abstract

In 30 patients with previously untreated open-angle glaucoma an intraocular pressure (IOP) curve was taken before and during treatment with PGF2 alpha-isopropylester (PGF2 alpha-IE) eye drops in one eye. Compared with the pretreatment IOP, the PGF2 alpha-IE induced a slowly increasing reduction in IOP. Just before the first dose the IOP was 31.4 (SEM 1.6) mm Hg. When corrected for the fall in pressure observed in the fellow eye the largest reduction, 5.8 (SEM 0.7) mm Hg (p less than 0.001), was obtained 24 hours later, that is, 12 hours after the second dose. In a subgroup of 10 patients the treatment was continued for one week. In this group the final pretreatment IOP was 25.9 (SEM 1.3) mm Hg. The reduction 24 hours later was 4.5 (SEM 0.6) mm Hg (p less than 0.001). The effect was maintained and even slightly increased during the week, and on the seventh day of treatment the IOP reduction ranged between 4.8 and 7.6 mm Hg compared with the pretreatment IOP. No serious subjective or objective side effects were observed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611194      PMCID: PMC1041949          DOI: 10.1136/bjo.73.12.975

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes.

Authors:  F A Stern; L Z Bito
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-05       Impact factor: 4.799

2.  Eicosanoids as a new class of ocular hypotensive agents. 2. Comparison of the apparent mechanism of the ocular hypotensive effects of A and F type prostaglandins.

Authors:  M Hayashi; M E Yablonski; L Z Bito
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-10       Impact factor: 4.799

3.  Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.

Authors:  C B Camras; S M Podos; J S Rosenthal; P Y Lee; C H Severin
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-03       Impact factor: 4.799

4.  Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha.

Authors:  K Crawford; P L Kaufman
Journal:  Arch Ophthalmol       Date:  1987-08

5.  Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys.

Authors:  K Crawford; P L Kaufman; B T Gabelt
Journal:  Curr Eye Res       Date:  1987-08       Impact factor: 2.424

6.  The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester.

Authors:  L Z Bito; R A Baroody
Journal:  Exp Eye Res       Date:  1987-02       Impact factor: 3.467

7.  The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.

Authors:  P Y Lee; H Shao; L A Xu; C K Qu
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-10       Impact factor: 4.799

8.  The effects of prostaglandin F2 alpha in the human eye.

Authors:  G Giuffrè
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

9.  Effects of intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle.

Authors:  P L Kaufman
Journal:  Exp Eye Res       Date:  1986-11       Impact factor: 3.467

10.  Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha.

Authors:  C B Camras; L Z Bito
Journal:  Curr Eye Res       Date:  1981       Impact factor: 2.424

View more
  12 in total

Review 1.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

2.  The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

Authors:  M Diestelhorst; S Roters; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

Review 3.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  S S Patel; C M Spencer
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 4.  Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.

Authors:  Peter G Klimko; Najam A Sharif
Journal:  Br J Pharmacol       Date:  2018-05-17       Impact factor: 8.739

5.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

Review 6.  A risk-benefit assessment of drugs used in the management of glaucoma.

Authors:  T Taniguchi; Y Kitazawa
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

7.  Latanoprost--a promising new glaucoma drug.

Authors:  S Nagasubramanian
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

Review 8.  Pharmacological advances in the treatment of glaucoma.

Authors:  J B Serle
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

9.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

10.  PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension.

Authors:  J Villumsen; A Alm
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.